Cash and cash equivalents were about $2 million at June 30, with an undrawn $10 million related-party credit line.
Q2 results and expenses
NeOnc posted a Q2 net loss of $14.2 million, or $(0.58) per diluted share, widening from a $5.7 million loss a year earlier.
Research and development expense more than doubled to $2.6 million from $0.7 million, while general and administrative expense edged down to $0.9 million from $1 million.
Operating expenses totaled $14.07 million, including $5.65 million of noncash stock-based compensation; non-GAAP operating expenses excluding that charge were $8.42 million.
Clinical and regulatory updates
The company confirmed an Aug. 12 investor call to present topline Phase 2a NEO100 data.
It also said it secured UAE IND clearances for NEO100 and NEO212.
NTHI•
